Finally, the utility of our lead DB-lipidoid was demonstrated through hepatic delivery of Cas9 mRNA/sgRNA for gene editing of transthyretin (TTR) and human fibroblast growth factor 21 (FGF21)-encoded mRNA for the treatment of obesity and fatty liver. The gene discussed is TTR; the disease is Obesity.